CSF3 and Miyoshi myopathy: In conclusion, PEG and its biosimilar (BIO/PEG) are advantageous, demonstrating improved efficacy and a superior safety profile compared with BIO/G-CSF in patients with MM who were conditioned with HDM prior to ASCT.